Compare PAGS & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | RCUS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | 2018 |
| Metric | PAGS | RCUS |
|---|---|---|
| Price | $9.61 | $23.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $11.71 | ★ $29.38 |
| AVG Volume (30 Days) | ★ 3.7M | 2.1M |
| Earning Date | 02-19-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 16.68 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,662,823,389.00 | $240,000,000.00 |
| Revenue This Year | $14.61 | N/A |
| Revenue Next Year | $5.39 | N/A |
| P/E Ratio | $7.12 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $6.11 | $6.50 |
| 52 Week High | $11.16 | $26.40 |
| Indicator | PAGS | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 58.02 |
| Support Level | $9.61 | $22.60 |
| Resistance Level | $9.86 | $23.62 |
| Average True Range (ATR) | 0.24 | 1.12 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 26.79 | 61.57 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.